ChemComm

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: A. Gianella, A. J. Czajkowska, F. Hoeben, H. Janssen, P. Jarzyna, D. Cormode, K. D. Costa, S. Rao, O. Farkhzad, R. S. Langer, Z. Fayad and W. Mulder, *Chem. Commun.*, 2013, DOI: 10.1039/C3CC43618G.



This is an *Accepted Manuscript*, which has been through the RSC Publishing peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, which is prior to technical editing, formatting and proof reading. This free service from RSC Publishing allows authors to make their results available to the community, in citable form, before publication of the edited article. This Accepted Manuscript will be replaced by the edited and formatted Advance Article as soon as this is available.

To cite this manuscript please use its permanent Digital Object Identifier (DOI®), which is identical for all formats of publication.

More information about *Accepted Manuscripts* can be found in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics contained in the manuscript submitted by the author(s) which may alter content, and that the standard **Terms & Conditions** and the **ethical guidelines** that apply to the journal are still applicable. In no event shall the RSC be held responsible for any errors or omissions in these *Accepted Manuscript* manuscripts or any consequences arising from the use of any information contained in them.

RSCPublishing

PSC Publishing

www.rsc.org/chemcomm Registered Charity Number 207890 Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxx

ARTICLE TYPE

Synthesis and in vitro evaluation of a multifunctional and surfaceswitchable nanoemulsion platform

Anita Gianella^a, Aneta J. Mieszawska^a, Freek J.M. Hoeben^b, Henk M. Janssen^b, Peter A. Jarzyna^a, David P. Cormode^a, Kevin D. Costa^c, Satish Rao^c, Omid C. Farokhzad^d, Robert Langer^e, Zahi A. Fayad^a, ⁵ Willem J.M. Mulder^a*

Received (in XXX, XXX) Xth XXXXXXXX 20XX, Accepted Xth XXXXXXXX 20XX DOI: 10.1039/b000000x

We present a multifunctional nanoparticle platform that has targeting moieties shielded by a matrix metalloproteinase-2 10 (MMP2) cleavable PEG coating. Upon incubation with MMP2 this surface-switchable coating is removed and the targeting ligands become available for binding. The concept was evaluated in vitro using the biotin and $\alpha\nu\beta3$ -integrinspecific RGD-peptide functionalized nanoparticles.

- ¹⁵ Intravenously administrable nanoparticles can be used in a variety of biomedical applications that range from targeted drug delivery, target-specific imaging, nucleic acid delivery to thermal therapy.^{1,2} The nanoparticle coating is of key importance as it greatly influences pharmacokinetics and bioavailability as well as ²⁰ the nanoparticle's ability to target a diseased site.³ Polymeric coatings, such as a polyethylene glycol (PEG) coating, provide shielding, reduce recognition and subsequent removal by the mononuclear phagocyte system (MPS), and therefore are applied to the majority of nanoparticles used for intravenous
- ²⁵ administration.¹ To enhance specificity and induce nanoparticle uptake by cells, target-specific molecules can be conjugated to the nanoparticle's coating.^{1,2} However, the exposure of targeting moieties at the surface may counteract the shielding effect of the polymeric surface coating and can cause augmented recognition ³⁰ by the MPS. In addition, off-target binding to epitopes expressed
- by vascular components such as endothelial or circulating cells can also reduce accumulation of nanoparticles at their target site.
- To deal with the aforementioned limitations of ligand functionalized nanoparticles we have developed a highly flexible ³⁵ nanoemulsion (Fig. 1a), based on a previously reported platform,⁴ of which the coating can be removed by matrix metalloproteinase-2 (MMP2).⁵ We have chosen for an MMP2 cleavable site as the enzyme is highly expressed at a variety of pathological sites, including solid tumors and atherosclerotic ⁴⁰ plaques.^{6,7} Upon nanoparticle accumulation at the pathological tissue and exposure to MMP2, the coating is 'removed' and the targeting moieties become available for binding. The nanoemulsion core consists of soybean oil and the coating is comprised of a mixture of cholesterol, PEG350 phospholipids
- ⁴⁵ (mPEG350-DSPE), PEG phospholipids functionalized with targeting moieties (i.e. biotin or RGD functionalized PEG1000 lipids), as well as a MMP2 cleavable methoxy-polyethylene

glycol (PEG)-lipid (mPEG-MMP2p-DSPE, Fig. 1b) to provide shielding. A description of the synthesis of the nanoemulsion and ⁵⁰ mPEG-MMP2p-DSPE is provided in the Supporting Information.



Fig. 1 (a) Schematic of the biotin functionalized and surface-switchable nanoemulsion platform. (b) Structure of MMP2 cleavable mPEG-MMP2p-DSPE (with mPEG being mPEG2000).

As a model for targeting and to robustly demonstrate the effect of shielded versus unshielded nanoemulsions we designed experiments where plain nanoemulsions, which had biotin-PEG1000-DSPE and the non-cleavable mPEG3000-DSPE ⁵⁵ incorporated, were used. Avidin, a 66 kDa protein with 4 binding sites for biotin, can induce nanoparticle aggregation, if the nanoparticles are unshielded and biotin is exposed, and can therefore serve as a model for targeting. By varying the lipid composition of the corona (cholesterol, mPEG350-DSPE, ⁶⁰ mPEG3000-DSPE, and biotin-PEG1000-DSPE) we were able to create nanoemulsions with different coating types (Table S.1). The avidin-induced aggregation was monitored with dynamic light scattering (DLS), while targeting of Rhodamine labeled nanoemulsions was evaluated on an avidin coated 96-well plate ⁶⁵ using a plate reader (Fig. S1, S2).

Surface switchable nanoemulsions were obtained by incorporation of mPEG-MMP2p-DSPE into the formulation. Based on the aforementioned model aggregation and binding experiments, we prepared nanoemulsions using the minimum of 45

10% PEG shielding (thereby permitting maximum MMP2 access to the cleavable peptide), 2.5% biotin to ensure good binding to avidin, and optionally replacing the uncleavable mPEG3000-DSPE by the MMP2 cleavable lipid mPEG-MMP2p-DSPE 5 (Table S.2). Through HPLC analysis we evaluated the nanoparticle composition after synthesis (Fig. S.10), which was found to be very similar to the starting phospholipid mixture (Table S.3), thereby proving the integrity of the nanoemulsion synthesis.



Fig. 2 (a) Avidin-induced aggregation of biotin functionalized nanoemulsions. Nanoparticle relative size was measured by DLS. (b) Nanoemulsion binding to an avidin monolayer. Normalized fluorescence of unshielded control nanoemulsions, as well as non-treated and MMP2-treated surface-switchable nanoemulsions. Mean \pm SD (N=3). § vs 10% PEG-shielded 2.5% biotin nanoparticles (P \leq 0.05), , vs 10% PEG-MMP2p-shielded 2.5% biotin nanoparticles before MMP2 treatment (P \leq 0.05).

The nanoemulsions were left untreated or treated with MMP2 before conducting aggregation or binding experiments. We observed that mPEG-MMP2p-DSPE containing nanoemulsions that were not pre-incubated with MMP2 (Fig. 2a) or that were ¹⁵ incubated with inactive MMP2 (Fig. S.11) did not aggregate upon incubation with avidin, similar to the control nanoemulsions that contained either 10% or 20% mPEG3000-DSPE (Fig. S.2a). Conversely, MMP2-treated mPEG-MMP2p-DSPE containing nanoemulsions did aggregate and the relative particle size was ²⁰ found to increase by a factor 2 to 3, similar to the control nanoemulsions with the freely exposed biotin-PEG-DSPE (and 0% mPEG3000-DSPE) (Fig. 2a). MMP2 dose effects on the cleavage are shown in Fig. S.12.

To mimic binding to epitopes expressed at cells, we performed ²⁵ binding experiments with an avidin monolayer using the same samples and conditions as for the above-described aggregation experiment. To that end we used avidin coated 96-well plates and incubated the wells with the different samples for 30 min. Rhodamine labeled phospholipids were included in the lipid

³⁰ corona of the nanoemulsions so that their binding could be measured by recording the fluorescence with a plate reader. Similar to the aggregation experiment, and in line with the aforementioned hypothesis, we observed binding for the unshielded control nanoemulsions and, crucially, for the mPEG-³⁵ MMP2p-DSPE nanoemulsions that were pretreated with MMP2 (Fig. 2b).

In a further evaluation of the nanoemulsion binding characteristics, we developed a self-assembled monolayer (SAM)

method that enabled the functionalization of gold-silicon (Au-Si) ⁴⁰ wafers with avidin and imaging with atomic force microscopy (AFM). The 2D-AFM image in Fig. 3c clearly shows elevated binding of mPEG-MMP2p-DSPE containing nanoemulsion treated with MMP2 to the surface as compared to the control sample (Fig. 3b).



Fig. 3 Typical 2D-AFM images of Au-Si wafers after incubation with (a) avidin only, (b) avidin and then a 10% mPEG3000-DSPE with 2.5% biotin-PEG1000-DSPE nanoemulsion and (c) avidin and then a 10% mPEG-MMP2p-DSPE with 2.5% biotin-PEG1000-DSPE nanoemulsion previously treated with MMP2.

To confirm that the aggregation/binding was induced by cleaving of the mPEG2000 moiety we performed mass spectrometry on mPEG-MMP2p-DSPE that was left untreated or incubated with MMP2 for 12 hrs. Mass spectrometry revealed the ⁵⁰ mPEG2000 cleavage product in the sample incubated with MMP2 (Fig. S.13).

The kinetics of PEG cleavage was also investigated. To that end the nanoemulsions were incubated with MMP2 for different time spans, ranging from 1 to 12 hours, while avidin-induced ⁵⁵ aggregation was used as the readout method. As shown in Fig. S.14b, 12 hours of MMP2 treatment was necessary to induce the ligand exposure. A similar timeframe has been shown by others to induce the in vitro cleavage of cancer pro-drugs conjugated with MMP2 sensitive peptides.¹⁶ However, it is important to ⁶⁰ consider that in vitro conditions do not fully reflect the in vivo situation. We purposely and carefully designed our nanoparticles to have a PEG-density and ligand density that requires relatively long MMP2 exposure in order for the PEG to be cleaved off. Indeed, in experiments where we have exposed the nanoemulsions to serum protein (FBS), we have seen a high stability of the nanoparticles (Fig. S.15).

Protease induced nanoparticle aggregation has been suggested to be useful in medical and biochemical assays as well as to preserve good pharmacokinetics of target-specific 70 nanoparticles.^{8,9} In for example tumor targeting, a number of epitopes of interest that are expressed at tumor cells are also expressed by cells of the MPS and, more importantly, by the diseased endothelium. An example of such an epitope is the avβ3-integrin, which is an excellent tumor vasculature marker for 75 nanoparticle targeting,¹⁰ but targeting of this integrin expressed at tumor cells is difficult as, upon intravenous administration, the nanoparticles are exposed and bind to the vascular endothelium first and therefore can only marginally extravasate into the tumor interstitium.¹¹ Because RGD peptides are known to have a high ⁵ affinity for $\alpha\nu\beta3$ -integrin, we have functionalized our platform with c[RGDfK]-DSPE (full synthetic details are included in the Supporting Information). As for biotin-PEG1000-DSPE, c[RGDfK]-DSPE has been designed such that the c[RGDfK] targeting units protrude from the nanoemulsion platform after



Fig. 4 Flow cytometry histograms of HUVEC, MDA MB 231 and J774A1 cells incubated with (i) 0% mPEG3000 and 2.5% RGD nanoemulsions, (ii) 10% mPEG3000 and 2.5% RGD nanoemulsions and (iii) 10% PEG-MMP2p and 2.5% RGD nanoemulsions after MMP2 treatment.

10 MMP2 cleavage of the mPEG-MMP2p-DSPE lipid.

Human umbilical vein endothelial cells (HUVEC) and breast cancer cells (MDA-MB-231), that both are known to express high levels of $\alpha\nu\beta3$ -integrin, as well as murine macrophage (J774A1) ¹⁵ were treated with RGD functionalized control nanoemulsions and surface switchable nanoemulsions. Flow cytometry revealed a clear difference in nanoparticle-cell association when the RGD moieties were available for targeting, i.e. at 0% mPEG3000 and at 10% mPEG-MMP2p-DSPE after MMP2 treatment (Fig. 4).

- Lastly, to examine the versatility of our nanoemulsion platform, we included either oleic acid coated iron oxide (IO) or oleyl mercaptan coated gold (Au) nanocrystals as well as the lipophilic drug simvastatin in mPEG-MMP2p-DSPE functionalized nanoemulsion samples to render so-called
- 25 theranostic nanoparticles, exhibiting both therapeutic and diagnostic properties. In Supp. Fig. 20a and 20b we present DLS size and polydispersity measurements as well as transmission electron microscopy (TEM) images of these theranostic nanoemulsions. For the Au nanoemulsions the attenuation
- ³⁰ characteristics, measured in Hounsfield Units (HU) per mM (SFig. 20a), revealed good CT contrast generating properties (Fig. 5, top), similar to that of a clinically applied iodinated CT contrast agent (Isovue, Bracco Diagnostic). As a measure for the IO nanoemulsion's potential to serve as an MRI contrast
- ³⁵ generating material we acquired the longitudinal and transverse relaxivities r1 and r2 at 60 MHz (Supp. Fig. 20a). Clear MR hypo-intensities are generated by IO loaded nanoemulsions as is shown in Fig. 5 (bottom). The drug inclusion for the final Au formulation was measured using 1H-NMR spectroscopy (Fig.
- ⁴⁰ S.21). Simvastatin encapsulation efficiency (encapsulated drug/input) was established to be 57.2% of the initial input value, and the loading efficiency was 1.43% (weight drug/weight oil).



Fig. 5 CT (top) and MR (bottom) images of Au and IO theranostic nanoemulsion phantoms.

In summary we have presented a self-assembled and ⁴⁵ multifunctional nanoemulsion platform that is surface-switchable upon exposure to MMP2. The inclusion of diagnostically active materials and drugs is straightforward. We believe our nanoemulsion platform may be useful in a variety of conditions that are associated with MMP2 (over)expression, including ⁵⁰ cancer.

This work was supported by the National Heart, Lung, and Blood Institute, National Institutes of Health, as a Program of Excellence in Nanotechnology (PEN) Award, Contract #HHSN268201000045C, as well as by R01 EB009638 (Z.A.F.), 55 K99 EB012165 (D.P.C.), S10 RR027609 (K.D.C.), and R01 CA155432 (W.J.M.M.).

 ^a Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
 ^b SyMO-Chem B.V., Eindhoven, The Netherlands;

^c Cardiovascular Cell and Tissue Engineering Laboratory, Cardiovascular Research Center, Mount Sinai School of Medicine, New York, NY, USA;

^d Laboratory of Nanomedicine and Biomaterials, Department of

65 Anesthesiology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA;

^e Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; E-mail: <u>willem.mulder@mssm.edu</u>

† Electronic Supplementary Information (ESI) available: Methods and Supprting Figures. See DOI: 10.1039/b000000x/

References

- 1 D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, *Nat.Nanotechnol.* 2007, **2**, 751-760.
 - 2 M. E. Lobatto, V. Fuster, Z. A. Fayad, W. J. M. Mulder, Nat.Rev.Drug Discov. 2011, 11, 835-52
- 3 S. M. Moghimi, A. C. Hunter, J. C. Murray, *Pharmacol.Rev.* 2001, 53, 283-318.
- 80 4 P. A. Jarzyna, T. Skajaa, A. Gianella, D. P. Cormode, D. D. Samber, S. D. Dickson, W. Chen, A. W. Griffioen, Z. A. Fayad, W. J. M. Mulder, *Biomaterials*. 2009, **30**, 6947-6954.
- 5 C. Chang, Z. Werb. Trends in Cell Biology. 2001, 11, S37-S43.
- Z. Li, L. Li, H. R. Zielke, L. Cheng, R. Xiao, M. T. Crow, W. G.
 Stetler-Stevenson, J. Froehlich, E. G. Lakatta, Am.J.Pathol. 1996, 148 121-128.
- 7 L. Nakopoulou, I. Tsirmpa, P. Alexandrou, A. Louvrou, C. Ampela, S. Markaki, P. S. Davaris, Breast Cancer Res Treat. 2003, 77 145-155.
- 90 8 T. J. Harris, G. von Maltzahn, A. M. Derfus, E. Ruoslahti, S. N. Bhatia, Angew.Chem.Int.Ed Engl. 2006, 45 3161-3165.
- 9 P. M. Winter, S. D. Caruthers, A. Kassner, T. D. Harris, L. K. Chinen, J. S. Allen, E. K. Lacy, H. Zhang, J. D. Robertson, S. A. Wickline, G. M. Lanza, Cancer Res. 2003, 63 5838-5843.
- 95 10 W. J. M. Mulder, G. J. Strijkers, J. W. Habets, E. J. Bleeker, D. W. van der Schaft, G. Storm, G. A. Koning, A. W. Griffioen, K. Nicolay, FASEB J. 2005, 19 2008-2010.